Health
Rheumatoid arthritis drug tied to fewer deaths in COVID patients – CIDRAP
In both studies, patients receiving tocilizumab had about half the risk of dying.
Two new studies have revealed that the rheumatoid arthritis drug tocilizumab is associated with lower death rates in COVID-19 patients receiving mechanical ventilation. Tocilizumab blocks interleukin-6 (IL-6), an inflammatory protein involved in a potential “cytokine storm” that can lead to respiratory failure in coronavirus patients.
In the first single-center observational study, published late last week in Clinical Infectious Diseases, University of Michigan at Ann Arbor researchers found that tocilizumab was linked to a 45% reduction in risk of death (hazard ratio
-
Business16 hours agoAged 30 and earning an average wage? You’re now set up for retirement. Here’s how
-
General22 hours agoAustralia’s mental health plan ‘not fit for purpose’ and must be re-designed, new report finds
-
Noosa News21 hours agoAssault charges, Nambour – Sunshine Coast
-
General20 hours agoDigital nanny deep state | The Spectator Australia